Key Stats for Amgen Stock
- Current Price: $432.42
- Target Price (Mid): ~$495
- Street Target: ~$388
- Potential Total Return: ~14%
- Annualized IRR: ~3% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Amgen Inc. (AMGN) closed at $432.42 on August 28, near an all-time high and above the $388 average analyst price target, which means the market is now paying more for the stock than the Street thinks it is worth. Shares have returned roughly 51% over the past year, and the August 4 Q2 report gave the rally more fuel: quarterly revenue crossed $10 billion for the first time, and management raised full-year guidance for both revenue and earnings.
The discomfort is that the price has moved past the people who cover it. When a stock trades above consensus after a 51% run, a buyer is no longer betting the story is real. They are betting it runs further than the analysts modeling it currently expect. That is a narrower bet, and it deserves an honest look at what the price already assumes.
Every Growth Driver Is Already in the Number
The quarter was strong, and that is exactly why the stock has little cushion. Revenue rose 9.5% to $10.05 billion, beating the Street by nearly 7%, while adjusted earnings of $6.29 came in almost 12% ahead of consensus. Free cash flow reached $3.5 billion, and management lifted the 2026 adjusted EPS midpoint to roughly $22.90.
The mix is what re-rated the stock. Six growth drivers grew 26% in aggregate and now supply close to 70% of product sales, so Amgen leans less on the denosumab franchise that biosimilars are eroding. Repatha rose 37% to $953 million, EVENITY 38%, TEZSPIRE 42%, and UPLIZNA 90%. Chief Commercial Officer Murdo Gordon said Repatha’s growth is now split roughly in half between cardiologists writing more per physician and an expanding base of primary care doctors treating high-risk primary prevention patients.
The market has absorbed the beat, the raise, and the driver story, and at $432, the stock trades near 18.4x forward earnings, toward the high end of its own recent range.
See historical and forward estimates for Amgen stock (It’s free!) >>>
What the Premium Requires, and What Could Break It
Against biotech peers, Amgen does not screen as expensive: its 18.4x forward earnings sits above AbbVie at 16.8x, Gilead at 15.9x, and Biogen at 16.5x, a modest premium that its scale and dividend arguably justify. The tension is not the peer premium. It is that Amgen’s own forward revenue is modeled to compound at just 3% to 4% a year, because the new franchises are still climbing while Prolia, XGEVA, and Enbrel decline. A low-single-digit grower trading above consensus is priced for the pipeline and the core franchises to keep outrunning that model, with little room for a stumble.
In July 2026, the FDA approved Merck’s enlicitide (Lipfendra), the first oral PCSK9 inhibitor, taking direct aim at Repatha, Amgen’s largest single product. Gordon pushed back on the call, arguing the labels “just don’t compare,” citing Repatha’s outcomes data in both primary and secondary prevention and noting the oral option carries food restrictions in its first 30 minutes. He also pointed to fresh evidence: in the VESALIUS-CV trial, Repatha cut three-point major adverse cardiovascular events by 29% in high-risk diabetes patients and produced a nominal 21% reduction in all-cause death. That data strengthens Repatha’s case, but an approved oral competitor in a market this size is a real variable a buyer at this price is absorbing.
Of the analysts covering the stock, 10 rate it Buy and 4 Outperform, but 16 sit at Hold with 2 Underperforms and 2 Sells, and the average target still sits below the market price. There is also a live overhang: in an Item 1.05 filing dated July 31, Amgen disclosed a cybersecurity incident in which patient health information and proprietary data were exfiltrated from third-party cloud storage. It deemed the incident material enough to report, while stating separately that it does not expect a material impact on its financial condition.
See how Amgen performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $432.42
- Target Price (Mid): ~$495
- Potential Total Return: ~14%
- Annualized IRR: ~3% / year
See analysts’ growth forecasts and price targets for Amgen stock (It’s free!) >>>
Using the mid-case, TIKR’s model puts Amgen at around $495 by 2030, roughly 14% total return, or about 3% a year. That is the honest answer to the chase question: at today’s price, the base case pays a low-single-digit annual return plus a dividend near 2.3%, closer to a bond than a growth stock.
- Revenue drivers: the maturing growth franchises led by Repatha’s push into primary prevention, and the Rare Disease portfolio, where UPLIZNA is growing 90% across three approved indications.
- Margin driver: non-GAAP operating margin holding near 45% to 46% as Horizon acquisition amortization rolls off.
- Primary risk: the model already assumes only low-single-digit growth, so an approved oral PCSK9 competitor pressuring Repatha, or faster legacy erosion, pulls the base case down rather than up.
- Upside: the obesity asset MariTide converts its Phase III program into a repricing event, the current multiple only partly credits.
- Downside: the stock treads water as a mid-single-digit total-return holding while the pipeline proves itself.
Conclusion
The decision here rests on a single fact: the stock trades above where the Street values it, so the margin of safety is gone, and execution has to stay perfect. The next print on November 2 is the near-term test of whether the six growth drivers keep outrunning the legacy declines and whether Repatha holds share against Merck’s new oral competitor. A clean quarter that keeps consensus targets rising would justify paying up. Any crack, a Repatha slowdown, or a guidance wobble, and a buyer is left holding a low-growth stock at a full price with analysts already below the market. Above consensus and near record highs, the burden of proof now sits with the buyer.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Amgen?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Amgen, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Amgen alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
